Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | 0.82% | 44.25 | 0.9% | $1537.37m | |
| JNJ | Johnson & Johnson | -0.60% | 163.77 | 0.7% | $982.08m | |
| ABBV | AbbVie, Inc. | -1.30% | 106.33 | 1.9% | $978.80m | |
| MRK | Merck & Co., Inc. | 0.36% | 71.94 | 0.7% | $799.95m | |
| LLY | Eli Lilly & Co. | 0.77% | 231.86 | 1.1% | $599.11m | |
| BMY | Bristol-Myers Squibb Co. | -1.27% | 60.53 | 1.0% | $545.22m | |
| AZN | AstraZeneca Plc | 5.29% | 58.50 | 1.0% | $274.88m | |
| NVS | Novartis AG | -0.82% | 82.80 | 0.2% | $167.64m | |
| SNY | Sanofi | -1.01% | 47.89 | 0.2% | $136.30m | |
| GSK | GlaxoSmithKline Plc | -0.23% | 38.84 | 0.2% | $122.59m | |
| RPRX | Royalty Pharma Plc | -4.34% | 36.83 | 0.1% | $113.92m | |
| NVO | Novo Nordisk A/S | -1.71% | 99.68 | 0.1% | $107.46m | |
| VTRS | Viatris, Inc. | -1.77% | 13.33 | 0.0% | $107.28m | |
| RGEN | Repligen Corp. | -0.28% | 306.05 | 6.8% | $102.70m | |
| APLS | Apellis Pharmaceuticals, Inc. | -3.36% | 33.06 | 0.0% | $93.67m |
Company Profile
Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.